Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
[forminator_form id="25163"]

bloomberg.com.investor.insmed.com+1.ca.investing.com+1.Sanofi is considering an acquisition of Insmed , according to people familiar with the matter cited by Bloomberg. Bloomberg said the deal would be the largest biopharma transaction in years. The Paris-based drugmaker is talking with advisers as it studies a possible bid for the New Jersey company, which specializes in respiratory and rare diseases. Insmed shares rose sharply in morning trading on Thursday, November 19.bloomberg.com
The news shows Sanofi moving toward the larger, late-stage deals its new leadership has been signaling. Insmed would bring a fast-growing commercial lung drug at a time when Sanofi needs growth to replace its blockbuster Dupixent.
Deliberations are ongoing, and a deal could still be weeks away, Reuters reported, citing the Bloomberg report. Insmed had a market value of about $26.28 billion based on LSEG data, the Reuters story carried by Yahoo Finance said. Sanofi's interest may not produce an agreement, and other bidders could emerge, according to Investing.com. Representatives for both companies declined to comment to Bloomberg. Trading in Insmed stock was briefly halted by a volatility circuit breaker after the report, while Sanofi shares fell in Paris, Investing.com reported. The report did not mention a price or deal terms.reuters.com+3
Most of Insmed's appeal comes from Brinsupri, its bronchiectasis drug. The company said in its third-quarter results that Brinsupri brought in $400.1 million, up 29% from the prior quarter. Total revenue was $524.4 million, and Insmed raised its 2026 Brinsupri guidance to $1.35 billion to $1.4 billion. At the Jefferies healthcare conference, Chief Executive Will Lewis said the drug could eventually reach at least $7 billion in peak sales, MarketBeat reported. Insmed expects its three lead respiratory programs to bring in more than $14 billion in combined peak sales, and it expects to become cash-flow positive in 2027, according to The Globe and Mail.investor.insmed.com+2
Belén Garijo became Sanofi's CEO in May and has said the company is ready to do bigger deals. Finance chief François Roger said in October that Sanofi would look beyond its usual $2 billion to $5 billion range to buy late-stage or marketed medicines, Reuters reported. Analysts estimate the company has about €20 billion available for deals. Dupixent made up 39% of Sanofi's net sales last quarter and loses patent protection in 2031, BioSpace noted. Sanofi recently expanded its partnership with Regeneron in a deal worth up to $8 billion. It also completed its purchase of Dynavax in February, according to its half-year report.sec.gov+2
"We are laser-focused on ensuring growth beyond Dupixent," Garijo told analysts last month, according to BioSpace.biospace.com